Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Schmitt, Esther ^a   Végran, Frédérique ^a,b   Chevrier, Sandy ^a   Burillier, Laura ^a   Cadouot, Muriel ^a   Lizard Nacol, Sarab ^a   Coudert, Bruno ^a   Fumoleau, Pierre ^a   Arnould, Laurent ^a,b   Boidot, Romain ^a,b  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b Institut Médical de Génétique et d Immunologie   (France)

Author keywords

Breast; First line neoadjuvant treatment; HER2; Response prediction; Trastuzumab + docetaxel

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TAXOID; TUMOR PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CTNS GENE; DERL 1 GENE; FAM114A2 GENE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIAA1549 GENE; MICROARRAY ANALYSIS; ONCOGENE; P2RX1 GENE; PITPNA GENE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PSMD11 GENE; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; WEE1 GENE; AGED; BIOSYNTHESIS; BREAST NEOPLASMS; CANCER STAGING; DRUG EFFECTS; GENETIC DATABASE; GENETICS; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DATABASES, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEOPLASM STAGING; RECEPTOR, ERBB-2; TAXOIDS; TRASTUZUMAB;

EID: 84928953112     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1198-9     Document Type: Article

References (14)

1. Coudert BP, Arnould L, Moreau L, Chollet P, Weber B, Vanlemmens L, et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol. 2006;17:409-14.
2. Coudert BP, Largillier R, Arnould L, Chollet P, Campone M, Coeffic D, et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol. 2007;25:2678-84.
3. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460-9.
4. Végran F, Boidot R, Coudert B, Fumoleau P, Arnould L, Garnier J, et al. Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma. Br J Cancer. 2009;101:1357-64.
5. Liu JC, Voisin V, Bader GD, Deng T, Pusztai L, Symmans WF, et al. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer. Proc Natl Acad Sci U S A. 2012;09:5832-7.
6. Glück S, Ross JS, Royce M, McKenna Jr EF, Perou CM, Avisar E, et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat. 2012;132:781-91.
7. Shen K, Qi Y, Song N, Tian C, Rice SD, Gabrin MJ, et al. Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial. BMC Med Genomics. 2012;5:51.
8. Humbert O, Berriolo-Riedinger A, Riedinger JM, Coudert B, Arnould L, Cochet A, et al. Changes in 18 F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Ann Oncol. 2012;23:2572-7.
9. 18 F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1525-33.
10. Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore Jr I, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013;14:1121-8.
11. Lara Jr PN, Laptalo L, Longmate J, Lau DH, Gandour-Edwards R, Gumerlock PH, et al. California Cancer Consortium. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 2004;5:231-6.
12. Yan Y, Lu L, Liu C, Li W, Liu T, Fu W. HER2/neu over-expression predicts poor outcome in early gastric cancer without lymph node metastasis. Clin Res Hepatol Gastroenterol. 2015;39:121-6.
13. Dai GH, Shi Y, Chen L, Lv YL, Zhong M. Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression. Hepatogastroenterology. 2012;59:2439-44.
14. Crown J, Kennedy MJ, Tresca P, Marty M, Espie M, Burris HA, et al. Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Ann Oncol. 2013;24:2005-11.